Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
DALLAS - Taysha Gene Therapies, Inc. (NASDAQ: TSHA), a clinical-stage biotech company specializing in gene therapies for central nervous system diseases, with a current market capitalization of $528 million, announced today the launch of a public offering of its common stock and pre-funded warrants. According to InvestingPro data, the company maintains a strong liquidity position with its liquid assets exceeding short-term obligations, though it’s currently experiencing rapid cash burn. The company, which is advancing treatments for severe monogenic CNS diseases, will also offer underwriters a 30-day option to purchase additional shares, including those underlying the pre-funded warrants.
The offering’s completion, size, and terms remain subject to market conditions, and no guarantees have been made regarding its finalization. Jefferies, BofA Securities, Piper Sandler, and Barclays are managing the offering as joint book-runners. The timing of this offering comes as the stock has seen a significant -9.86% decline over the past week, though it maintains a positive YTD return of over 50%. Get deeper insights into Taysha’s financial health and 12 additional exclusive ProTips with an InvestingPro subscription.
Taysha’s commitment to addressing severe medical needs and improving patient lives is demonstrated by its lead clinical program, TSHA-102, which targets Rett syndrome—a rare neurodevelopmental disorder lacking approved therapies that address its genetic cause. While the company holds more cash than debt on its balance sheet, analysts anticipate a sales decline in the current year, with comprehensive analysis available in the Pro Research Report on InvestingPro.
The securities will be offered pursuant to a shelf registration statement filed with the Securities and Exchange Commission (SEC) on December 13, 2024, and declared effective on December 20, 2024. Relevant documents, including a preliminary prospectus supplement and accompanying prospectus, will be available on the SEC’s website and through the book-running managers’ contacts.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor will there be any sale in jurisdictions where such offer, solicitation, or sale would be unlawful before registration or qualification under the local securities laws.
The information disclosed is based on a press release statement by Taysha Gene Therapies. The forward-looking statements within the release reflect the company’s expectations and are subject to risks that could cause actual results to differ significantly. These include uncertainties related to the public offering’s market conditions and Taysha’s research and development plans. Further details on these risks can be found in Taysha’s SEC filings.
In other recent news, Taysha Gene Therapies reported a positive earnings result for Q1 2025, with an earnings per share (EPS) of -$0.08, surpassing analyst expectations of -$0.09. The company’s revenue also exceeded forecasts, reaching $2.3 million against a predicted $1.91 million. This financial performance highlights Taysha’s effective cost management and strategic investments in research and development. Additionally, Taysha is advancing towards a pivotal trial for its gene therapy candidate TSHA-102 for Rett syndrome, following alignment with the U.S. Food and Drug Administration (FDA). The trial is set to begin in the third quarter of 2025 and will involve 15 patients. Baird maintains an Outperform rating on Taysha, reiterating a $7 price target, reflecting confidence in the company’s regulatory progress and potential. These developments have positioned Taysha as a notable entity in the biotech sector, particularly with its focus on addressing significant unmet medical needs in gene therapy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.